- Home
- DSX vs YMAB Comparison
DSX vs YMAB Comparison
Compare DSX & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSX
- YMAB
- Stock Information
- Founded
- DSX 1999
- YMAB 2015
- Country
- DSX Greece
- YMAB United States
- Employees
- DSX N/A
- YMAB N/A
- Industry
- DSX Marine Transportation
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DSX Consumer Discretionary
- YMAB Health Care
- Exchange
- DSX Nasdaq
- YMAB Nasdaq
- Market Cap
- DSX 172.5M
- YMAB 192.4M
- IPO Year
- DSX 2005
- YMAB 2018
- Fundamental
- Price
- DSX $1.55
- YMAB $8.51
- Analyst Decision
- DSX
- YMAB Buy
- Analyst Count
- DSX 0
- YMAB 11
- Target Price
- DSX N/A
- YMAB $15.02
- AVG Volume (30 Days)
- DSX 242.6K
- YMAB 1.5M
- Earning Date
- DSX 07-30-2025
- YMAB 08-08-2025
- Dividend Yield
- DSX 2.60%
- YMAB N/A
- EPS Growth
- DSX 41.44
- YMAB N/A
- EPS
- DSX 0.12
- YMAB N/A
- Revenue
- DSX $224,186,000.00
- YMAB $85,385,000.00
- Revenue This Year
- DSX N/A
- YMAB N/A
- Revenue Next Year
- DSX $12.09
- YMAB $15.23
- P/E Ratio
- DSX $13.03
- YMAB N/A
- Revenue Growth
- DSX N/A
- YMAB N/A
- 52 Week Low
- DSX $1.27
- YMAB $3.55
- 52 Week High
- DSX $2.63
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- DSX 47.42
- YMAB 81.64
- Support Level
- DSX $1.46
- YMAB $4.16
- Resistance Level
- DSX $1.58
- YMAB $8.54
- Average True Range (ATR)
- DSX 0.05
- YMAB 0.24
- MACD
- DSX -0.01
- YMAB 0.47
- Stochastic Oscillator
- DSX 38.64
- YMAB 99.32
About DSX Diana Shipping inc. common stock
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.